tumor-associated transplantation antigen (TSTA)

over 94% identical with tum- antigen P198; found in fractions derived from cytosol of the Meth A sarcoma cells; chemically induced neoplasms contain individually distinct TATA; are immunogenic in their syngeneic hosts & provide transplantation immunity only to their respective tumors & not similarly induced tumors

Also Known As:

Networked: 176 relevant articles (11 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gambhir, Sanjiv S: 7 articles (05/2012 - 03/2002)
2.	Wu, Lily: 7 articles (10/2011 - 03/2002)
3.	Carey, Michael: 6 articles (01/2006 - 03/2002)
4.	Gambhir, S S: 4 articles (06/2011 - 12/2001)
5.	Iyer, Meera: 4 articles (01/2006 - 03/2002)
6.	Zhang, Liqun: 4 articles (05/2005 - 03/2002)
7.	Kim, Sung Wan: 3 articles (08/2012 - 10/2006)
8.	Lee, Minhyung: 3 articles (08/2012 - 10/2006)
9.	Sato, Makoto: 3 articles (10/2011 - 11/2003)
10.	Carey, M: 3 articles (04/2008 - 12/2001)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2012 - "With intratumoral delivery, Ad-pSurvivin-TSTA-TRAIL-FL showed positive FL signal from all tumors and better therapeutic efficacy than Ad-pCMV-FL on day 7 (2.4 ± 0.50 vs 5.4 ± 0.78; P = .01). " 05/01/2012 - "With intravenous delivery, Ad-pSurvivin-TSTA-TRAIL-FL showed no measurable liver tumor FL signal on day 1 after delivery, but showed better therapeutic efficacy than Ad-pCMV-FL on day 7 (PET tumor/liver ratio, 3.5 ± 0.58 vs 6.0 ± 0.71; P = .02). " 09/01/1984 - "Moreover, the strongly immunogenic LTC-1 hybrid cells, but not the parent tumor cells, were effective in priming recipient spleen cells to generate TEPC-15 tumor-specific cytotoxic cells upon subsequent in vitro exposure to the TSTA-bearing cells. " 01/01/2006 - "The results from this study support the use of TSTA-based lentiviral vectors for prostate tumor targeting after systemic delivery. " 08/01/1990 - "Thus, this study demonstrates that Ag other than TSTA on chemically induced tumors can serve as target molecules for T cell-mediated adoptive immunotherapy."
2.	Prostatic Neoplasms (Prostate Cancer) 05/15/2005 - "A highly augmented, prostate-specific two-step transcriptional amplification (TSTA) method was developed with the ultimate goal of delivering an effective and safe gene-based treatment to prostate cancer patients. " 08/01/2006 - "A two-step transcriptional amplification system (TSTA) was used to enhance the efficacy of suicide gene therapy for treatment of prostate cancer. " 03/01/2007 - "These results highlight that the recombinant PPT sequence is active in murine prostate cancer cells when augmented by a TSTA system. " 03/01/2007 - "Herein, we describe that the PPT sequence in combination with a two-step transcriptional amplification (TSTA) system becomes active also in murine prostate cancer cells. " 05/15/2005 - "Together with the fact that majority of recurrent prostate cancers express AR and PSA, we foresee that the TSTA approach can be a promising gene therapy strategy for the advanced stages of prostate cancer."
3.	Sarcoma (Soft Tissue Sarcoma) 01/01/1989 - "Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas." 10/15/1984 - "Isolation of a tumor-associated transplantation antigen (TATA) from an SV40-induced sarcoma. " 04/01/1984 - "These procedures provide a means for successful separation of immunogenic SV40- and Adv-7-induced TSTA from detectable, biologically active, cross-protective EA from the surfaces of these sarcoma cells." 01/01/1982 - "Rabbits immunized with the immunoprotective TSTA fraction partially purified by preparative isoelectric focusing of 3 M KCl extracts from a chemically induced murine sarcoma, MCA-F, produced specific xenoantisera as assessed by an indirect membrane immunofluorescence assay. " 12/01/1981 - "These results suggest that in the Meth A sarcoma a transforming gene and a genetic determinant of TSTA are intimately related: they may be identical or very closely linked; alternatively, a particular transforming gene might induce the expression of a particular TSTA. "
4.	Fibrosarcoma 04/15/1983 - "In this study we have analyzed the in vitro cell-mediated cytotoxicity of immune peritoneal exudate cells (PEC), elicited in syngeneic mice against the MCA-induced, TSTA-bearing BALB/c fibrosarcoma CA-2, GI-17 and C-3. " 05/01/1983 - "We have analyzed the complexity of a unique tumor-specific transplantation antigen expressed by the murine ultraviolet light-induced fibrosarcoma 1591-RE. " 12/01/1978 - "Genetic control of responsiveness to the tumor-associated transplantation antigen of a chemically induced murine fibrosarcoma." 08/15/1987 - "The weakly immunogenic murine fibrosarcoma MCA-F was used because we have previously characterized the tumor-specific transplantation antigen expressed by this tumor. " 07/15/1987 - "Two polyoma-TSTA-negative variants were selected independently from a polyoma fibrosarcoma/Moloney lymphoma somatic hybrid, by repeated passages in polyoma-virus-preimmunized mice. "
5.	Neoplasm Metastasis (Metastasis) 10/01/2011 - "Moreover, intravenous administrated PSES-TSTA bioluminescent vector correctly identified tibial bone marrow metastases in 9 of 9 animals, whereas NaF- and FDG-PET was unable to detect the lesions. " 12/20/1984 - "[The immunotherapeutic effect of partially purified tumor specific transplantation antigen against pulmonary metastasis]." 10/01/1980 - "acnes) on metastasis formation of C3H/He mice which has been rendered tolerant to tumor-associated transplantation antigen (TATA) of syngeneic X5563 plasmacytoma. " 01/01/1988 - "In a spontaneous pulmonary metastasis model following amputation of a tumor-bearing limb, the triple regimen of TSTA/CY/RTT-2 markedly reduced the number of lung colonies. " 01/01/1988 - "In a spontaneous pulmonary metastasis model following amputation of a tumor-bearing limb, only the triple regimen of TSTA/CY/i.s.-IL-2 decreased the number of lung colonies and prolonged host survival. "

Related Drugs and Biologics

1.	Methylcholanthrene
2.	Histocompatibility Antigens (Histocompatibility Antigen)
3.	Telomerase (Telomerase Reverse Transcriptase)
4.	Interleukin-2 (IL2)
5.	Epitopes
6.	Gal-VP16
7.	Therapeutic Uses
8.	telomerase RNA (bTR)
9.	Antigens
10.	Histocompatibility Antigens Class I

Related Therapies and Procedures

1.	Transplantation
2.	Therapeutics
3.	Injections
4.	Intravenous Administration
5.	Surgical Amputation (Amputations)